The cardiovascular outcomes, heart failure and kidney disease trials tell that the time to use Sodium Glucose Cotransporter 2 inhibitors is now-Reference-Cited by-同舟云学术

The cardiovascular outcomes, heart failure and kidney disease trials tell that the time to use Sodium Glucose Cotransporter 2 inhibitors is now

Published:2020-11-09 Issue:12 Volume:43 Page:1376-1387
ISSN:0160-9289
Container-title:Clinical Cardiology
language:en
Short-container-title:Clin Cardiol

Author:

Johansen Michael E.¹,Argyropoulos Christos²^ORCID

Affiliation:

1. Grant Family Medicine OhioHealth Columbus Ohio USA

2. Division of Nephrology University of New Mexico School of Medicine Albuquerque New Mexico USA

Publisher

Wiley

Subject

Cardiology and Cardiovascular Medicine,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/clc.23508

Reference33 articles.

1. Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes

2. Pooled analysis of Phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin

3. Effects of the sodium–glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and Stages 3b–4 chronic kidney disease

4. Food & Drug Administration HHS.Endocrinologic and Metabolic Drugs Advisory Committee; Notice of meeting. Fed Regist2008;73(100):29762.

5. A study of the effects of hypoglycemic agents on vascular complications in patients with adult‐onset diabetes. II. Mortality results;Meinert CL;Diabetes,1970

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Chronic Kidney Disease in the Older Adult Patient with Diabetes;Journal of Clinical Medicine;2024-01-08

2. Pharmacist-Led Review of Empagliflozin and Ertugliflozin Following Formulary Update;The American Journal of Managed Care;2023-08-01

3. Quand et comment utiliser les inhibiteurs de SGLT2 ou gliflozines en pratique clinique ? Un consensus proposé par la Société francophone du diabète (SFD), la Société française de cardiologie (SFC), le Collège national des cardiologues français (CNCF) et la Société francophone de néphrologie, dialyse et transplantation (SFNDT);Néphrologie & Thérapeutique;2023-08-01

4. Association of Sodium-Glucose Cotransporter 2 Inhibitors with Osteomyelitis and Other Lower Limb Safety Outcomes in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomised Controlled Trials;Journal of Clinical Medicine;2023-06-09

5. Sodium–glucose cotransporter 2 inhibitors vs. sitagliptin in heart failure and type 2 diabetes: an observational cohort study;European Heart Journal;2023-06-01